Novo Nordisk Receives FDA Warning Letter Over Misleading GLP-1 Promotional Video Featuring Wegovy, Ozempic, and Victoza

Novo Nordisk's promotional compliance posture is under direct regulatory scrutiny after FDA's Center for Drug Evaluation and Research (CDER) issued a warning letter on September 9, 2025, citing a direct-to-consumer video as false or misleading under the Federal Food, Drug and Cosmetic Act. The letter, addressed to President and CEO Maziar Mike Doustdar, covers three semaglutide and liraglutide products simultaneously: Wegovy, Ozempic, and Victoza.

The video in question, titled "An Oprah Special: Shame, Blame, and the Weight Loss Revolution," aired as an ABC Primetime Special on March 18, 2024, and subsequently on Hulu. FDA determined the content misbrands all three products under 21 U.S.C. 352(a) and (n), rendering its distribution violative. Two paid consultants who receive research funding from GLP-1 manufacturers appeared in the video alongside Novo Nordisk's Senior Vice President of Cardiometabolic Sales, a combination FDA found created a misleading impression of the products' safety profiles.

The agency's core concern centers on risk communication. All three products carry serious, potentially life-threatening risks, and Wegovy specifically carries a boxed warning for thyroid C-cell tumors, with contraindications in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. FDA cited 21 CFR 202.1(e)(5) and (e)(7)(viii) in its misbranding determination, and separately noted that the materials were not submitted at the time of initial dissemination as required under 21 CFR 314.81(b)(3)(i), compounding the compliance exposure.

For regulatory affairs leads, the dual violation structure is the sharper operational signal: substantive misbranding findings and a procedural submission failure under Part 314 are being cited together, which typically elevates the remediation burden. DTC content involving paid consultants with disclosed financial relationships to the manufacturer warrants heightened pre-dissemination review, particularly where products carry boxed warnings targeting vulnerable populations including pediatric patients.

Novo Nordisk's response to CDER's required corrective action commitments will set a measurable benchmark for how the company recalibrates its promotional review and submission workflows across its GLP-1 portfolio.

Source: FDA CDER via FDA Warning Letters RSS Feed, September 9, 2025; letter dated September 9, 2025, published June 23, 2026.